| |
| |
|
| Insider
Information: |
Meckler Jeffrey A |
| Relationship: |
CEO and Director, Dire... |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
914,035 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,730,045 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
914,035 |
|
|
| Total
Value |
$1,730,045 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
8
|
0
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
6
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -24.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Novelion Therapeutics Inc |
NVLN |
Director |
2015-06-29 |
107,000 |
2013-05-03 |
0 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Director |
2023-05-17 |
74,500 |
2014-10-08 |
0 |
Premium* |
|
|
Cocrystal Pharma |
COCP |
|
2016-03-15 |
657,161 |
2014-12-11 |
0 |
Premium* |
|
|
Intec Parent Inc. |
INDP |
CEO and Director, Dire... |
2022-11-21 |
75,374 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
74,500 |
0 |
- |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2022-11-21 |
4 |
B |
$1.90 |
$18,240 |
D/D |
9,600 |
75,374 |
2.81 |
- |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2022-11-18 |
4 |
B |
$1.76 |
$705 |
D/D |
400 |
65,774 |
2.73 |
% |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2022-09-08 |
4 |
B |
$2.80 |
$28,862 |
D/D |
10,308 |
65,374 |
2.81 |
% |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2022-09-07 |
4 |
B |
$2.57 |
$22,184 |
D/D |
8,632 |
55,066 |
2.81 |
% |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2022-09-06 |
4 |
B |
$2.44 |
$2,586 |
D/D |
1,060 |
46,434 |
2.73 |
% |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2022-06-06 |
4 |
B |
$2.63 |
$51,882 |
D/D |
19,727 |
45,374 |
2.81 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2022-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
70,000 |
0 |
- |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2021-11-18 |
4 |
B |
$5.82 |
$65,108 |
D/D |
11,187 |
25,647 |
2.81 |
% |
|
| INDP |
Intec Parent Inc. |
CEO and Director |
• • – |
2021-09-14 |
4 |
B |
$7.00 |
$84,000 |
D/D |
12,000 |
14,460 |
2.81 |
% |
|
| INDP |
Intec Parent Inc. |
Chief Executive OfficerOfficer |
• • – |
2021-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,460 |
|
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
67,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
64,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
61,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2018-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
59,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
56,500 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2016-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
54,000 |
0 |
- |
|
| COCP |
Cocrystal Pharma |
CHIEF EXECUTIVE OFFICER |
• • – |
2016-03-15 |
4 |
B |
$0.51 |
$150,000 |
D/D |
294,118 |
657,161 |
2.81 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2016-03-04 |
4 |
B |
$15.31 |
$76,565 |
D/D |
5,000 |
52,000 |
2.39 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2016-03-03 |
4 |
B |
$14.45 |
$144,500 |
D/D |
10,000 |
47,000 |
2.39 |
- |
|
| COCP |
Cocrystal Pharma |
CHIEF EXECUTIVE OFFICER |
• • – |
2015-12-23 |
4 |
B |
$0.58 |
$57,870 |
D/D |
100,000 |
363,043 |
2.81 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2015-06-29 |
4 |
OE |
$3.30 |
$87,125 |
D/D |
25,000 |
107,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2015-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
37,000 |
0 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2015-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
82,000 |
0 |
- |
|
| COCP |
Cocrystal Pharma |
|
– • – |
2015-03-25 |
4 |
B |
$0.92 |
$150,000 |
D/D |
163,043 |
263,043 |
2.39 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
